Brainstorm Cell Therapeutics, Inc. [BCLI] stock is trading at $0.65, down -3.56%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BCLI shares have gain 15.28% over the last week, with a monthly amount glided 97.51%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 1, April 2024, BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update. In a post published today on Yahoo Finance, Conference call planned for early April 2024 to provide update on NurOwn program.
From an analyst’s perspective:
Brainstorm Cell Therapeutics, Inc. [NASDAQ: BCLI] stock has seen the most recent analyst activity on February 04, 2021, when Maxim Group upgraded its rating to a Buy but kept the price target unchanged to $12 for it. Previously, Maxim Group downgraded its rating to Hold on November 17, 2020. On December 19, 2016, Maxim Group reiterated its Buy rating and revised its price target to $6 on the stock. Maxim Group reiterated its Buy rating and decreased its price target to $5 on December 22, 2015.
Brainstorm Cell Therapeutics, Inc. [BCLI] stock has fluctuated between $0.13 and $3.37 over the past year. Brainstorm Cell Therapeutics, Inc. [NASDAQ: BCLI] shares were valued at $0.65 at the most recent close of the market.
Analyzing the BCLI fundamentals
Gross Profit Margin for this corporation currently stands at 3.03% with Operating Profit Margin at 62.5%, Pretax Profit Margin comes in at 50.12%, and Net Profit Margin reading is 49.85%. To continue investigating profitability, this company’s Return on Assets is posted at -4.06, Equity is 4.23 and Total Capital is 5.97. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6255 points at the first support level, and at 0.6001 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6807, and for the 2nd resistance point, it is at 0.7105.
Brainstorm Cell Therapeutics, Inc. [BCLI] reported earnings per share of -$0.27 for its fiscal quarter that ended on 6/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.15/share, meaning a difference of -$0.12 and a surprise factor of -80.00%. By comparison, the stated earnings for the previous quarter ended on 3/30/2023 were -$0.14 per share as compared to estimates of -$0.16 per share, a difference of $0.02 representing a surprise of 12.50%.
Ratios To Look Out For
For context, Brainstorm Cell Therapeutics, Inc.’s Current Ratio is 0.24. Further, the Quick Ratio stands at 0.24, while the Cash Ratio is 0.17.
Transactions by insiders
Recent insider trading involved Lindborg Stacy, Co-Chief Executive Officer, that happened on Sep 01 ’23 when 11500.0 shares were purchased.
